Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator
Authors:
Open Access
- 8 January 2015
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 22 (3) , 237-246
Abstract
Although oncolytic viruses have shown great promise as cancer therapeutics, results from a recent phase III clinical trial indicate that their potency may need further improvement for a clear clinical benefit. Here, we report a novel strategy to increase the bystander effect of virotherapy by arming an oncolytic virus with a secreted form of a Her2 single chain antibody linked to a self-multimerizing Fas ligand extracellular domain (Her2-COL-sFasL). The rationale is that, due to its much smaller size, this apoptosis activator can overcome obstacles such as the dense collagen in the tumor tissues to spread more freely than the viral particles. When measured in vitro, Her2-COL-sFasL was found to efficiently induce caspase cleavage, resulting in an 80% reduction in cell viability. Once incorporated into the genome of an oncolytic type 2 herpes simplex virus, FusOn-H3, Her2-COL-sFasL potentiates the therapeutic efficacy of the virus in an aggressive syngeneic mammary tumor model. Our data suggest that arming an oncolytic virus with a secretable and self-multimerizing apoptosis inducer is a feasible strategy to improve the potency of virotherapy.Keywords
This publication has 46 references indexed in Scilit:
- Production of multivalent protein binders using a self‐trimerizing collagen‐like peptide scaffoldThe FASEB Journal, 2008
- Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas AgonistsCancer Research, 2008
- Matrix Metalloproteinases-1 and -8 Improve the Distribution and Efficacy of an Oncolytic VirusCancer Research, 2007
- Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous systemNature, 2007
- Fas Ligand Delivery by a Prostate-Restricted Replicative Adenovirus Enhances Safety and Antitumor EfficacyClinical Cancer Research, 2007
- Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95LCell Death & Differentiation, 2007
- Induction of strong antitumor immunity by an HSV‐2‐based oncolytic virus in a murine mammary tumor modelThe Journal of Gene Medicine, 2007
- Serial Passage through Human Glioma Xenografts Selects for a Δγ 1 34.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain TumorsJournal of Virology, 2006
- A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic VirusMolecular Therapy, 2006
- Target Cell–Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7Cancer Research, 2005